

### EVENTITY (Romosozumab-aqqg) ORDER FORM

#### REFERRAL TYPE

- New Referral     
  Order Renewal     
  Restart     
  Frequency Change     
  Dosage Change

#### PREFERRED LOCATION

- |  |  |   |
|--|--|---|
| <input type="checkbox"/> 2730 University Blvd. West   Suite 714<br>Wheaton, MD 20902 | <input type="checkbox"/> 14995 Shady Grove Road   Suite 250<br>Rockville, MD 20850 | <input type="checkbox"/> 5454 Wisconsin Avenue   Suite 600<br>Chevy Chase, MD 20815 |
| <input type="checkbox"/> 18111 Prince Philip Drive   Suite 323<br>Olney, MD 20832    | <input type="checkbox"/> 71 Thomas Johnson Drive<br>Frederick, MD 21702            | <input type="checkbox"/> 2021 K Street, NW   Suite 300<br>Washington, DC 20006      |

#### PATIENT INFORMATION

Name:	DOB:	Email:
Address:		Weight: <span style="margin-left: 20px;">KG</span> <span style="margin-left: 20px;">LBS</span> Phone:

#### REFERRING PHYSICIAN INFORMATION

Name:	NPI:
Office Contact Name:	Phone: <span style="margin-left: 20px;">Fax:</span>
Address:	

#### EVENTITY ORDER

**Dosing/Frequency:**  
 Two 105mg injections (total of 210mg) once every month for 12 months

**Diagnosis:**  
 M81.0—Age-related osteoporosis without current pathological fracture  
 M81.8—Other osteoporosis without current pathological fracture

Other Diagnosis: ICD-10 Code (Required):

**Special Instructions:**

Physicians Signature:	Date: <span style="float: right;"><i>(Order is Valid for One Year)</i></span>
-----------------------	---

#### REQUIRED DOCUMENTATION

- Please fax the following documents and records:**
- Patient Demographics
  - Copy of the patient’s insurance card(s) – front and back
  - Two most recent office notes (Supporting the DX and treatment ordered)
  - Medication History
  - Most recent labs that include values for:
    - Serum or ionized calcium (drawn within the last 6 months)
    - 25OH Vitamin D ≥20ng/ml (drawn within the last year)
  - For continuation of treatment, include the last infusion note
  - Most Recent DEXA with images
  - Documentation reflecting failure of two bisphosphonates

***We will contact the patient and schedule their treatment once our benefit investigation and any prior authorizations have been completed.***